Identification of outcome domains in immune checkpoint inhibitor-induced inflammatory arthritis and polymyalgia rheumatica: A scoping review by the OMERACT irAE working group.

Autor: Ghosh N; Department of Medicine, Division of Rheumatology, Hospital for Special Surgery/Weill Cornell Medical College, 535 E 70th St, New York, NY, USA. Electronic address: ghoshn@hss.edu., Couette N; Department of Internal Medicine. Division of Rheumatology & Immunology, The Ohio State University, Columbus, OH, USA., van Binsbergen WH; Amsterdam Rheumatology and Immunology Center, Department of Rheumatology & Clinical Immunology, Amsterdam University Medical Center location DBL Amsterdam, the Netherlands., Weinmann SC; Department of Rheumatology & Immunology, Duke University, Durham, NC, USA., Jivanelli B; Hospital for Special Surgery, Kim Barrett Memorial Library, HSS Education Institute, New York, NY, USA., Shea B; School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada., Bass AR; Department of Medicine, Division of Rheumatology, Hospital for Special Surgery/Weill Cornell Medical College, 535 E 70th St, New York, NY, USA., Benesova K; Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, Heidelberg, Germany., Bingham CO; Division of Rheumatology, Johns Hopkins University, Baltimore MD, USA., Calabrese C; Department of Rheumatologic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, USA., Cappelli LC; Division of Rheumatology, Johns Hopkins University, Baltimore MD, USA., Chan KK; Department of Medicine, Division of Rheumatology, Hospital for Special Surgery/Weill Cornell Medical College, 535 E 70th St, New York, NY, USA., Choy E; CREATE Centre, Section of Rheumatology, Division of Infection and Immunity, Cardiff University, Cardiff, United Kingdom., Daoussis D; Department of Rheumatology, University of Patras Medical School, Patras University Hospital, Patras, Greece., Goodman S; Department of Medicine, Division of Rheumatology, Hospital for Special Surgery/Weill Cornell Medical College, 535 E 70th St, New York, NY, USA., Hudson M; Jewish General Hospital, Lady Davis Institute for medical research and McGill University, Montreal, Quebec, Canada., Jamal S; Vancouver Coastal Health, University of British Columbia, Vancouver, BC, Canada., Leipe J; Division of Rheumatology, Department of Medicine V, University Hospital Mannheim, Medical Faculty Mannheim of the University of Heidelberg, Germany., Lopez-Olivo MA; The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Suarez-Almazor M; Department of Health Services Research, University of Texas MD Anderson Cancer Center, Houston, TX, USA., van der Laken CJ; Amsterdam Rheumatology and Immunology Center, Department of Rheumatology & Clinical Immunology, Amsterdam University Medical Center location DBL Amsterdam, the Netherlands., Meara AS; Department of Internal Medicine. Division of Rheumatology & Immunology, The Ohio State University, Columbus, OH, USA., Liew D; Department of Rheumatology, Austin Health, Department of Clinical Pharmacology and Therapeutics, Austin Health, Australia, Department of Medicine, University of Melbourne, Parkville VIC, Australia., Kostine M; Bordeaux University Hospital, Department of Rheumatology, France.
Jazyk: angličtina
Zdroj: Seminars in arthritis and rheumatism [Semin Arthritis Rheum] 2023 Feb; Vol. 58, pp. 152110. Date of Electronic Publication: 2022 Oct 26.
DOI: 10.1016/j.semarthrit.2022.152110
Abstrakt: Introduction: Immune checkpoint inhibitors (ICI), increasingly used cancer therapeutics, can cause off-target inflammatory effects called immune-related adverse events (irAEs), including ICI-induced inflammatory arthritis (ICI-induced IA) and polymyalgia rheumatica (ICI-induced PMR). There are no validated classification criteria or outcome measures for these conditions, and adaptation of treatment recommendations from corresponding rheumatic diseases may not be appropriate. We summarized clinical descriptors of ICI-induced IA and ICI-induced PMR and aggregated domains used for these conditions in order to inform the development of a core set of outcome domains.
Methods: As the initial step of the core domain set generation process, we systemically searched Medline (Pubmed), EMBASE, Cochrane, and CINHL through March 2021 to identify all studies that provide both clinical descriptions and domains relevant to ICI-induced IA and ICI-induced PMR. Domains were mapped to core areas, such as pathophysiological manifestations, life impact, resource use, and longevity/survival, as suggested by the OMERACT 2.1 Filter.
Results: We identified 69 publications, over a third of which utilized non-specific diagnoses of "arthritis," "arthralgia," and/or "PMR". Other publications provided the number, the distribution and/or names of specific joints affected, while others labeled the irAE as the corresponding rheumatic disease, such as rheumatoid arthritis or spondyloarthritis. Most distinct domains mapped to the pathophysiology/manifestations core area (24 domains), such as signs/symptoms (13 domains), labs (6 domains), and imaging (5 domains), with harm domains of adverse effects from irAE treatment and fear of irAE treatment decreasing ICI efficacy. Forty-three publications also referenced irAE treatment and 35 subsequent response, as well as 32 tumor response.
Conclusion: There is considerable heterogeneity in the domains used to clinically characterize ICI-induced IA and ICI-induced PMR. There were several domains mapped to the pathophysiologic manifestations core area, although several publications highlighted domains evenly distributed among the other core areas of life impact, longevity/survival and resource use.
Competing Interests: Declarations of Competing Interest CB - Consulting: AbbVie, BMS, Eli Lilly, Janssen, Moderna, Pfizer, Sanofi; Grant support: BMS. EC - Research grants from Bio-Cancer, Biogen, Novartis, Pfizer, Roche, Sanofi and UCB, consultancy from Abbvie, Amgen, Biogen, Biocon, Chugai Pharma, Eli Lilly, Gilead, Janssen, Merck Serono, Novartis, Pfizer, Regeneron, Roche, RPharm and Sanofi, speakers fee from Abbvie, Amgen, Bristol Myer Squibbs, Chugai Pharma, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, Regeneron, RPharm, Roche, Sanofi, and UCB. JL - grant/research support from: Novartis, Pfizer; Abbvie, BMS, Gilead, Janssen, Sanofi; honoraria for consulting or speaking: Abbvie, BMS, Galapagos Janssen-Cilag, Gilead, Lilly, Medac, MSD, Novartis, Pfizer, Roche/Chugai, Sanofi, UCB. LC – Supported by AR075872 from NIAMS, Consulting: Bristol-Myers Squibb, Tremeau Pharmaceuticals, Mallinckrodt Pharmaceuticals. Research Funding: Bristol-Myers Squibb. MK - Consulting/speaker fees: Bristol-Myers Squibb, Janssen-Cilag, MSD, Novartis. KB -Consultancy and/or speaker fees and/or travel reimbursements: Abbvie, Bristol Myers Squibb (BMS), Gilead/Galapagos, Janssen, Merck Sharp & Dohme (MSD), Mundipharma, Novartis, Pfizer, Roche, Viatris, UCB. Scientific support: Medical Faculty of University of Heidelberg, Rheumaliga Baden-Württemberg e.V., AbbVie, Novartis. MH - Advisory boards: Boehringer Ingelheim, Alexion, Mallinckrodt; Research grants: Boehringer Ingelheim, Bristol Myers Squibb. CC - speaker and consulting for Sanofi/Regeneron. MSA- Pfizer, Eli Lilly, Avenue Therapeutics, Chemocentryx, Gilead, Bristol Myers Squibb, AMAG, Agile Therapeutics. SG: Grant from Novartis, Advisory board for UCB, ACR guideline subcommittee chair. MLO - National Cancer Institute and Rheumatology Research Foundation. All other co-authors have no declarations.
(Copyright © 2022. Published by Elsevier Inc.)
Databáze: MEDLINE
Externí odkaz: